AntriaBio Pullback Could Spell Opportunity

AntriaBio, Inc. (ANTB.OB) is another still-developing player in the sector of diabetes treatment that has recently pulled back and could be worth a look to both short- and long-term investors. This company is bringing to human trials over the near term a once-a-week basal insulin shot (AB101) that would look to replace the once-daily current standard of care. The noted benefits to a patient's quality of life that this product could have to those currently needing a shot a day is obvious, and AntriaBio shares have the potential to move in-line with catalysts as they develop during the coming quarters - especially in light of the recent pullback. After hitting highs of over two roughly a month ago, the share price has trickled lower on light volume, an indication that those who are already in are holding, while others looking to get in may do so when the see the share price settle. Given the relatively light volume, however, this one could still be trading below the radar - but that could change as progress is made this year in the clinical development of AB101.

Human trials in Russia are slated to begin over the near term and once data starts rolling in from those trials, then AntriaBio plans to use that data - assuming its positive - to search for potential partners, whether they be regional or international, according to a recent presentation (pdf). Diabetes is growing at a very rapid pace worldwide, as discussed in the SanuWave write-up, so AntriaBio could be positioning to enter a very lucrative market and could attract the swift interest of partners or potential acquirers if human trials move forward with success.

In addition to the above-mentioned catalyst events, FDA milestones could be forthcoming, as well, as the company has stated plans to proceed with the IND process in the U.S. while simultaneously conducting trials overseas. Emphasis has been put on the overseas trials first, however, due to significant costs benefits of conducting trials elsewhere, while patient recruitment is often easier, too. Once some human data is established, then it makes the FDA process at home a little bit easier. The path to approval should also be estimated as quicker than the standard drug approval process, due to the established nature of basal insulin, meaning developments could unfold quickly once trials are started.

Standard risks apply for developmental companies in the sector, but the recent price pullback, pending catalysts and overall potential of AB101 in the commercial market - should it make it that far - makes AntriaBio's recent trading action worth watching.

http://seekingalpha.com/article/1298501-weekly-stock-watch-week-of-march-25?source=yahoo

http://biotechintel.com/blog/2013/3/12/antria-bio-antb

Novo Nordisk - the world's largest insulin producer - and major diabetes drug manufacturers - could see BILLIONS in recurring revenue dry up as a small, California-based biotech company advances a technology that promises to change diabetes treatment.

Over $100,000,000 has been invested in developing this super-drug that threatens to make products like Sanofi's $6 BILLION-A-YEAR basal insulin - 'Lantus' - OBSOLETE.

The Company that's making executives in the world's largest pharmaceutical firms sweat is Menlo Park, California-based ANTRIABIO, INC. (ANTB)

Here's why large pharma is worried about ANTRIABIO's technology:

1. Basal insulin is prescribed as a once-daily injection; Antriabio is developing a once-weekly version.

2. Big Pharma long-ago realized the need for longer-acting insulin - but the best they've been able to produce is a thrice-weekly (3X per week) regimen.

3. But even the thrice-weekly regimen, developed by Novo Nordisk, was recently rejected by the FDA for marketing in the United States - the world's most lucrative diabetes market.

4. The FDA has made it clear that it will not compromise patient safety for Novo Nordisk's 'longer-acting' insulin drug.

5. Analysts estimate the FDA setback will cost Novo Nordisk BILLIONS and delay launch to 2018 or later, and perhaps indefinitely, because their drug has been linked to heart complications.

6. Antriabio's long-acting basal insulin is developed using a well-validated (PROVEN) and widely-accepted (SAFE) technology call PEGYlation. The company patented use of this technology with insulin, which makes virtually every competitor in diabetes OBSOLETE.

7. Market Research suggests that by 2018, sales of insulin will reach $32 BILLION globally, and every pharmaceutical company seeing revenue dry up because of expiring patents will want a piece of this ENORMOUS market.

8. In 2012, patent expiration cost pharmaceutical companies more than $34 BILLION in sales; the loss will balloon to $147 BILLION by 2015.

9. If global pharmaceuticals companies want to remain competitive, they'll need to find disruptive technologies with extensive patent life targeting large markets, and partner with or outright acquire such technologies. In other words, big pharma is seeking technologies like Antriabio's long-acting basal insulin - which to them is worth BILLIONS OF DOLLARS.

Big pharma is sitting on the largest stockpile of cash seen in history - cash that was accumulated selling lucrative drugs that will now go off-patent and cause losses to the tune of $147 BILLION in 2015 alone.


However, big pharma isn't sitting idle. Furthermore, executives at the world's largest pharmaceutical companies recognize their livelihood is at stake.

Big Pharma has progressively been acquiring disruptive technologies with long patent life targeting large markets like diabetes.

Last year, Bristol Myers Squibb spent $7 BILLION to acquire Amylin and their portfolio of GLP-1, a type of insulin prescribed to patients to help treat type-2 diabetes.

The acquisition of Amylin sparked a BIDDING WAR among:

1. AstraZeneca (AZN),

2. Pfizer (PFE)

3. Merck (MRK)

4. Sanofi Aventus (SNY)

5. Bristol Meyers Squibb (BMS)

This clearly proves that big pharma is not only interested but DESPERATE for products that will help them remain competitive.

What's incredible is that Antriabio has an even better version of Amylin's once-weekly GLP-1 drug - a super-long acting, once-monthly treatment.

To recap:

Novo Nordisk + Sanofi saw sales north of $8 BILLION just on their daily basil insulin product

Antriabio is developing a once-weekly version - called AB101 - that promises to make these existing products OBSOLETE

Bristol Myers Squibb paid $7 BILLION for Amylin's once-weekly GLP-1 insulin drug in 2012

Antriabio is developing a once-MONTHLY version of the GLP-1 drug - called AB201 - that sees annual sales of >$1 Billion.

We believe Antriabio will trade upwards as Big pharma continues to see their patents expire and suffer billions of dollars in recurring sales losses, Drug makers struggle to create SAFE, long-acting insulin products, Antriabio advances its technology and
Big pharma eventually bids to acquire Antriabio to eliminate the threat this small company poses and equally to secure a future worth BILLIONS to the big pharma companies who have established sales channels and distribution in diabetes care.
We like Antriabio as a company that is undiscovered by investors, boasts excellent management with a track record of success in biotech, and has strong intellectual property (IP) and patent life.
Last year, we saw Organovo, the world's first 3D Bio-Printing company quietly emerge as a public company. It debuted at $1.65 and rally to $11, before settling mid-range. Organovo successfully raised more than $25MM and is now weeks away from listing on a national exchange, likely the NASDAQ. Moreover, it is one of the most active issues traded over-the-counter. Organovo, like Antriabio, was once completely unknown to investors, but later emerged as one of the best-performing equities of 2012.


Organovo's disruptive technology in cell-based research suggests Antriabio should perform on par, if not better, during the course of this year, and beyond.

We anticipate Antriabio will be one of the best performing equities in 2013, supported by fundamentals that will eventually drive a large pharmaceutical company to acquire them at a huge premium to their current price. For some more information on Antriabio, view their overview.

?

Oh man... They evaluate company for at least a half Billion and will not sell it for less than that...

boom has been postponed... not for awhile...

congrats who was able to join/add today... expect to see a lot of activities tomorrow...

$90k/net per month => $1.08M annually (when 2 other wells will be production)

market cap should be from $9M to $10M... conservative pps is about $.02...

pps reflects the effect of BioMedReports. lol
Hopefully not for long...

Once-a-Week Insulin Shot Could Help Growing Diabetes Patient Base and Spell Huge Profits for Investors Marketwire   "Press Releases"

LOS ANGELES, CA -- (Marketwire) -- 02/22/13 -- In January 2013 , newly trading AntriaBio, Inc. (OTCQB: ANTB) acquired one of the most-interesting and buzzworthy assets we've seen in some time from a private company called PR Pharmaceuticals .

AntriaBio swooped in to snag the intriguing lead diabetes product, AB101, after that firm had already invested more than $100 million into the formulation, manufacturing and intellectual property development of the injectable once-a-week basal insulin solution for diabetics who are otherwise forced to take shots on a daily basis.

The team at AntriaBio was getting a great deal of attention at the recent Healthcare Conferences in San Francisco -- well before the company was even publicly trading as it is now. Why? Not only because the lead product had already seen substantial private capital development investment, but also because AB101 offers potential significant advantages over basal insulin products offered by Sanofi-Aventis and Novo Nordisk; whose products Lantus and Levemir have a combined $8B in annual sales.

From an investment standpoint, we like AntriaBio because the value for the lead product is clearly established but has not yet been recognized by the public markets. As their story begins to spread and more analysts begin to recognize its value, the stock price of this very-low-float company should begin to increase.

Looking at the situation from an industry standpoint, we have seen dozens of stories and several examples of industry titans buying once discarded unique assets with substantial market potential, for big money. See Amgen's acquisition of deCODE Genetics for $415MM in December 2012 as one.

"The company (deCODE) declared bankruptcy in 2009 and was rescued by some of its original investors, who acquired the firm and its assets for around $14 million and went on to invest another roughly $45 million ."

Literally weeks ago Baxter /Cangene stepped up to acquire an investigational hemophilia compound and other assets from the bankrupted Inspiration BioPharmaceuticals.

These biotechnologies were bought for pennies on the dollar and once their true value came to be recognized the acquisitions led to substantial profits.

The same should hold true for AntriaBio -- especially given that the incidence of diabetes is increasing rapidly and that this one-a-week insulin replacement therapy could be very appealing to individuals with diabetes who need to mimic healthy pancreas function by delivering insulin consistently day and night (basal insulin) and as needed following meals (bolus insulin).

In fact, if approved, AntriaBio believes AB101 will result in greater patient compliance (once weekly delivery versus once daily). Keep in mind, also, that the number of just over 300 million individuals with diabetes is expected to grow to be 550 million by 2030.

AntriaBio proposes that AB101 would be administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia. The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level that supplements the effects of bolus insulin and complements the effects of other diabetes medications.

The firm has a very smart and efficient clinical approval pathway that includes for the possibility that AB101 may be able to be marketed in Russia while US and EU studies move forward at a slower pace.

This is a fascinating and innovative technology led by a group with plenty of product experience and we will follow this story as it unfolds.

In the meantime, given the share-count actually in the float currently, it may be wise for both traders and long-term holders to consider establishing positions in front of upcoming catalysts and before this marked biotech's popularity begins to spread.

Disclosure: Author M.E. Garza is Long ANTB

The full version of this report complete with presentation slide deck images chart can be found here:

http://www.biomedreports.com/20130222124061/once-a-week-insulin-shot-could-help-growing-diabetes-patient-base-and-spell-big-profits-for-investors.html

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html

Follow Us

News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media Contacts Only: M. Davila Assistant Editor BioMedReports.Com e-mail: Email Contact

http://www.linkedin.com/jobs/jobs-Scientist-Analytical-Development-4821796

Scientist, Analytical Development - 2 Positions Available
AntriaBio, Inc. - Front Range (Greater Denver Area)

Job Description

This position is located in the vicinity of Denver, Colorado. As a member of the Research and Development group, works with AntriaBio team members in developing and validating analytical methods for sustained release formulations. Possesses a high level of expertise with proteins, peptides and biodegradable polymers. Experienced in using analytical methods in the general chapters and monographs in the USP/NF and Pharm. Eur. Experienced in ICH guidelines. Experienced in meeting corporate objectives. The specific job title will depend on the education, skills and experience of the candidate.
Desired Skills & Experience

- PhD strongly preferred. BS and MS candidates with relevant experience are encouraged to apply.

- Experience within pharmaceutical (bio) analytical methods development and validation.

- Experience in Quality Control and compliance with GLP.

- Experience with the use of separation chemistry based methods development and validation.

- Experience in writing CM&C sections for regulatory submissions.

- Experience in small to mid-size companies

- Superior interpersonal skills required. Must be able to establish peer relationships and communicate effectively with company disciplines, cross-functional, and external teams

- Experience in managing/leading cross-functional teams

- Proven ability to simultaneously manage activities associated with multiple projects and programs with short timelines.

- Attention to detail and commitment to high quality and on-time deliverables is required.

- Expert computer skills required.

- Proven ability to successfully manage people in matrix setting.

chart has been updated in the IBox

how is now?

AntriaBio Appoints Two Industry Leaders to Its Management Team

MENLO PARK, CA -- (Marketwire) -- 02/19/13 -- AntriaBio, Inc. (OTCQB: ANTB) is pleased to announce the appointment, on January 31, 2013 , of two new members to its management team: Nevan Elam , as AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada , Ph.D., as AntriaBio's Chief Scientific Officer.

Nevan Elam has spent his entire career starting, managing and advising emerging growth companies in key areas of business including finance, marketing and clinical development. Prior to joining AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical Limited , a medical device company based in Europe . Prior to that, he directed the Pulmonary Business Unit of Nektar Therapeutics, which was sold to Novartis in 2008.

Mr. Elam also serves as a managing director of Konus Advisory Group, Inc. ("Konus"), a boutique healthcare consulting and investment firm that specializes in working with U.S. and European healthcare organizations on business opportunities in Asia , Latin America and the Middle East . Mr. Elam holds a J.D. from Harvard University and Bachelor's degree from Howard University .

Sankaram Mantripragada , Ph.D. brings to AntriaBio his strong understanding of the diabetes market and AntriaBio's unique platform technology. From June 2005 until October 2009 , Dr. Mantripragada served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP"). In January 2013 , AntriaBio purchased substantially all of the PRP assets including significant technology, formulation, manufacturing, and intellectual property assets, which together form the basis of AntriaBio's drug development portfolio.

"Dr. Mantripragada's history with PRP's technology and formulation assets and his deep experience in diabetes products and markets make him a clear choice to lead our product development efforts," said Steve Howe , Executive Chairman of AntriaBio. Mr. Howe served as Chairman and Chief Executive Officer of PRP from its formation in 1998 to 2010.

Dr. Mantripragada has been an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He is listed as an inventor on more than eight patents.

Prior to joining PRP, Dr. Mantripragada served as Director of R&D at Guidant Corporation , now part of Abbott Vascular . Prior to that, he served as Director of R&D and VP of Scientific Development at SkyePharma. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine . Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany .

tomorrow could be last chance to enter at these bottom prices

found some good summaries here: http://pennystockhaven.com/mid-term-investment-opportunity-with-antriabio-fmyyd/

http://www.otcmarkets.com/financialReportViewer?symbol=CAVR&id=95712

Thank you, Renee

I expect to see AntriaBio's story unfold in a few weeks

AntriaBio Completes Merger and Elects Board of Directors

MENLO PARK, CA--(Marketwire - Feb 6, 2013) - AntriaBio Delaware, Inc. f/k/a AntriaBio, Inc. ("AntriaBio Delaware") ( OTCQB : FMYY ), a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the closing of its planned and previously announced merger with AntriaBio, Inc. f/k/a Fits My Style Inc., a Nevada corporation. Following the merger, the company is now listed as AntriaBio, Inc. ("AntriaBio"), and trading on the OTC Bulletin Board and the OTCQB under the symbol "FMYY." In connection with the merger, AntriaBio appointed three new directors.

As part of the terms of the merger, AntriaBio Delaware's stockholders received 35,284,000 newly issued shares of AntriaBio common stock, which constitutes approximately 88% of the issued and outstanding common stock of AntriaBio. Details of the share exchange transaction can be found in our current report on Form 8-K filed with the United States Securities and Exchange Commission.
Following the reverse merger, the directors of AntriaBio will include AntriaBio Delaware President and CEO Nevan Elam, AntriaBio Delaware Executive Chairman Steve R. Howe, Hoyoung Huh, M.D., Ph.D, and Nickolay V. Kukekov, Ph.D. Details on the appointments can be found on the Information Statement filed with the United States Securities and Exchange Commission on January 14, 2013.
Upon the closing of the asset purchase with PR Pharmaceuticals, Inc., AntriaBio's lead product candidate is AB101. AB101 is a once-a-week injectable basal insulin in preclinical development. AB101 is administered by subcutaneous injection and targets patients with Type 1 and Type 2 diabetes who require basal insulin for the control of hyperglycemia. The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week.

About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA-approved pharmaceutical agents with our proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.
For more information visit: www.antriabio.com

you'll be covering at $10 (if you're lucky). nothing personal...

how is the $10/share sound? :)

hold it buddy... believe me, you'll not be disappointed

no reaction on news? oh well...

[...]
The company also announced that it secured an equity capital injection from its management team that will immediately result in the completion of the rework and reentry of two producing wells on its Chisholm Lease, with the planned reentry into a 3rd well to follow in the near future. The Company expects cash flow initially to be $50,000 per month to CAVU ($35,000 net income), and once the third well is reentered and producing, the projected cash flow could increase to $90,000 per month. Supporting these efforts, and the coming further expansion, is a new equipment funding Line that CAVU has entered into that will accommodate most of its capital equipment needs for the foreseeable future.
[...]

new BOD member:

Mr. Watson brings over 35 years of experience in medical devices to Sunshine Heart, including 33 years at Medtronic, Inc., where he served in various roles of increasing responsibility spanning technical management, clinical and regulatory processes, business development, strategic marketing, and general management. Notably, he spent eight years as VP of Research and Development for the Cardiac Rhythm Management business. In addition to corporate officer roles, Mr. Watson has served on the Board of Directors of several U.S. cardiology companies. He was a member of the Board of California-based cardiology company, Cameron Health, which was bought by Boston Scientific in 2012. He currently serves on the Board of Cardialen, Inc. and Cardia Access, both Minneapolis-based early stage medical device companies.

in AU they had penny stock with Billions of outstanding (or so) - removing overhead is a step forward 4sho...

serious financial arms behind the Co.
could be Sarissa's story. eom

check background of this guy: Mark McLaughlin, Chairman of the Advisory Board ...

watching...

tomorrow should be fun

bought a few for next week...

http://antriabio.com/portfolio/team/

Pay attention to this guy:

Nickolay V. Kukekov, Ph.D.

Nickolay Kukekov is a Managing Director at Highline Research Advisors. Prior to forming Highline Research Advisors, a division of John Thomas Financial, Dr. Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research and, prior to that, was a Co-founder of the Healthcare Investment Banking group at Gilford Securities. Prior to joining Gilford, Dr. Kukekov was a Managing Director at Paramount BioCapital, where he ran the advisory, M&A and capital raising services for in-house private and public portfolio companies. Before that, he was a senior healthcare investment banker at Rodman & Renshaw. His scientific background includes a bachelor degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder and a Ph.D. in Neuroscience from Columbia University, College of Physicians and Surgeons in New York. Dr. Kukekov holds a number of research scholarship awards and peer review publications.

He was the financial arm behind MRIC at its run in July last year.

http://antriabio.com/careers/

Clinical Development Expert

Clinical Development expert with analytical scientific mind who will be responsible for clinical development strategy, clinical trial oversight and management, and support of clinical interactions with regulatory agencies and KOLs. This individual will also participate in identification of, and developing the long-range strategic plans for, AntriaBio pipeline products. The Director/Senior Director will lead the design, implementation, monitoring, analysis, and reporting of clinical studies and overall clinical programs supporting company pipeline products.

$2.25 x $2.45

Liquidity will come soon...

1.95 x 2.5

liquidity will be coming soon; going to trade as MRIC in July...

Symbol request sent to stockcharts.com

IBox with a basic info has been created. More to follow...

watching... may be a good bargain from the last-minute tax-loss seller...